Atlantic Trust Group LLC grew its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 19.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,382 shares of the medical instruments supplier’s stock after acquiring an additional 2,359 shares during the period. Atlantic Trust Group LLC’s holdings in C.R. Bard were worth $4,609,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of the business. Farallon Capital Management LLC acquired a new stake in shares of C.R. Bard in the second quarter valued at approximately $463,101,000. Alpine Associates Management Inc. acquired a new stake in shares of C.R. Bard in the second quarter valued at approximately $265,663,000. Pentwater Capital Management LP acquired a new stake in shares of C.R. Bard in the second quarter valued at approximately $139,088,000. York Capital Management Global Advisors LLC acquired a new stake in shares of C.R. Bard in the second quarter valued at approximately $122,678,000. Finally, CNH Partners LLC acquired a new stake in shares of C.R. Bard in the second quarter valued at approximately $116,100,000. Hedge funds and other institutional investors own 79.11% of the company’s stock.
A number of research firms have recently weighed in on BCR. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $372.00 price target for the company in a research report on Tuesday. Cowen reiterated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research report on Friday, November 3rd. Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. Jefferies Group reiterated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research report on Thursday, September 14th. Finally, ValuEngine downgraded shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $305.00.
In other C.R. Bard news, insider Sharon M. Luboff sold 30,252 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $320.00, for a total transaction of $9,680,640.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David M. Barrett sold 3,344 shares of the business’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $327.31, for a total transaction of $1,094,524.64. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 224,139 shares of company stock valued at $73,481,664. Company insiders own 0.80% of the company’s stock.
C.R. Bard, Inc. (NYSE BCR) opened at $333.41 on Wednesday. C.R. Bard, Inc. has a 1 year low of $221.75 and a 1 year high of $337.73. The company has a market cap of $24,220.00, a P/E ratio of 43.93, a price-to-earnings-growth ratio of 2.54 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the consensus estimate of $2.96 by $0.06. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The business had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. During the same period in the previous year, the business earned $2.64 earnings per share. The company’s revenue was up 5.1% on a year-over-year basis. equities research analysts anticipate that C.R. Bard, Inc. will post 11.89 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be given a dividend of $0.26 per share. The ex-dividend date is Thursday, December 7th. This represents a $1.04 annualized dividend and a yield of 0.31%. C.R. Bard’s dividend payout ratio is currently 10.28%.
COPYRIGHT VIOLATION WARNING: “Atlantic Trust Group LLC Raises Holdings in C.R. Bard, Inc. (BCR)” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://transcriptdaily.com/2017/12/27/atlantic-trust-group-llc-raises-holdings-in-c-r-bard-inc-bcr.html.
C.R. Bard Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.